ImmunoCellular Therapeutics (IMUC) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Maxim Group Downgrades ImmunoCellular Therapeutics (IMUC) to Hold
November 11, 2016 7:59 AM ESTMaxim Group downgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Buy to Hold.
Analyst Jason McCarthy highlighted:
IMUC reported 3Q16 with a net loss of $4.8M and ended the period with $15.3M in cash. With operating expenses of $6M per quarter, we estimate the company has sufficient funding well into 2017. In addition, funds from what remains of the $19.9M CIRM grant could further extend the cash runway and are payable based on... More